The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Melflufen and dex with bortezomib/daratumumab for myeloma: OP-104 study
Enrique Ocio, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses the Phase I/II OP-104 ANCHOR trial (NCT03481556) assessing the use of melflufen, an alkylating peptide, and dexamethasone in combination with either bortezomib or daratumumab in relapsed/refractory multiple myeloma (MM). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Ocio discusses the encouraging efficacy, in terms of response rates and safety, of these combinations, with early signs of activity seen after only 1 cycle of therapy.
